Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE- COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00079141" target="_blank" >RIV/65269705:_____/23:00079141 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/23:00132482

Výsledek na webu

<a href="https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300187" target="_blank" >https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300187</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300187" target="_blank" >10.2807/1560-7917.ES.2023.28.47.2300187</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE- COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Popis výsledku v původním jazyce

Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients &gt;= 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received &gt;= 14 days before symptom onset (stratifying first booster into received &lt; 150 and &gt;= 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received &gt;= 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset &lt; 120 days after first booster dose.

Název v anglickém jazyce

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE- COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Popis výsledku anglicky

Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients &gt;= 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received &gt;= 14 days before symptom onset (stratifying first booster into received &lt; 150 and &gt;= 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received &gt;= 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset &lt; 120 days after first booster dose.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Eurosurveillance

ISSN

1025-496X

e-ISSN

1560-7917

Svazek periodika

28

Číslo periodika v rámci svazku

47

Stát vydavatele periodika

SE - Švédské království

Počet stran výsledku

17

Strana od-do

2300187

Kód UT WoS článku

001117609400001

EID výsledku v databázi Scopus

2-s2.0-85177865991